MindMaze Therapeutics Holding (XSWX:MMTX) EV-to-EBIT: (As of Jul. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:MMTX MindMaze Therapeutics Holding SA XSWX:MMTX
4 GF Score
Price CHF0.16
! 2 Warning Signs
View Full Analysis

What is MindMaze Therapeutics Holding EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, MindMaze Therapeutics Holding's Enterprise Value is CHF17.23 Mil. MindMaze Therapeutics Holding does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate MindMaze Therapeutics Holding's EV-to-EBIT at this moment.

The historical rank and industry rank for MindMaze Therapeutics Holding's EV-to-EBIT or its related term are showing as below:

XSWX:MMTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -1.84   Med: 0   Max: 0
Current: -1.78
XSWX:MMTX's EV-to-EBIT is ranked worse than
100% of 376 companies
in the Biotechnology industry
Industry Median: 12.945 vs XSWX:MMTX: -1.78

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. MindMaze Therapeutics Holding's Enterprise Value for the quarter that ended in Dec. 2025 was CHF282.28 Mil. MindMaze Therapeutics Holding does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2025. Therefore, GuruFocus does not calculate MindMaze Therapeutics Holding's Earnings Yield (Joel Greenblatt) % at this moment.

MindMaze Therapeutics Holding  (XSWX:MMTX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

MindMaze Therapeutics Holding's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2025 ) =EBIT / Enterprise Value (Q: Dec. 2025 )
=/282.2768
= %

MindMaze Therapeutics Holding EV-to-EBIT Related Terms

MindMaze Therapeutics Holding EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for MindMaze Therapeutics Holding's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindMaze Therapeutics Holding EV-to-EBIT Chart

MindMaze Therapeutics Holding Annual Data
Trend Dec24 Dec25
EV-to-EBIT
0.00 -29.28

MindMaze Therapeutics Holding Semi-Annual Data
Dec24 Dec25
EV-to-EBIT 0.00 0.00

XSWX:MMTX vs VRTX, REGN, ALNY: EV-to-EBIT Comparison

For the Biotechnology subindustry, MindMaze Therapeutics Holding's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MindMaze Therapeutics Holding EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where MindMaze Therapeutics Holding's EV-to-EBIT falls into.


XSWX:MMTX
4GF Score
MindMaze Therapeutics Holding SA XSWX:MMTX
EV-to-EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindMaze Therapeutics Holding EV-to-EBIT Calculation

MindMaze Therapeutics Holding's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=17.234/
=

MindMaze Therapeutics Holding Business Description

Other Exchanges RLFTY:USAMMTXz:UK
Address Avenue de Secheron 15, Geneva, CHE, 1202
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
4GF Score

Get the complete analysis for XSWX:MMTX

EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF0.16
Price